In summary, our work investigated the tumour suppressive role of FTO and its downstream regulatory mechanism based on aberrant m6A modification in EBVaGC and uncovered that the FTO‐FOS‐IGF2BP1/2 signalling pathway delayed malignant progression in an m6A‐dependent manner. This evidence concerns the gene FOS and neoplasm.